NESTLÉ S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 101 EUR | +0.50% |
|
+3.48% | -3.81% |
| Jun. 07 | Nestlé Unit to Buy Vowst Assets from Seres Therapeutics | MT |
| Jun. 06 | Nestlé: acquisition of a drug derived from microbiota | CF |
Strengths
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's enterprise value to sales, at 3.26 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Sector: Food Processing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -3.81% | 289B | - | ||
| -6.38% | 91.47B | C+ | ||
| -7.00% | 41.98B | C+ | ||
| +2.28% | 41.91B | B- | ||
| +5.16% | 39.9B | B- | ||
| +3.56% | 38.04B | B- | ||
| -15.16% | 30.24B | B- | ||
| -5.86% | 28.57B | A | ||
| +8.15% | 24.63B | A- | ||
| -11.20% | 22.08B | A |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NESN Stock
- NESM Stock
- Ratings Nestlé S.A.
